Skip to content

Theravance Biopharma TBPH Other Income (Expense)

Other Income (Expense) at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$7.34M-313%
LQD
Liquidia CorporationLQDA
-$4.72M-60.5%
Royalty Pharma logo
Royalty PharmaRPRX
-$94.78M+5.0%
United Therapeutics logo
United TherapeuticsUTHR
-$7.5M-118%
Precigen logo
PrecigenPGEN
-$1.94M+93.9%
Organon logo
OrganonOGN
-$7M-275%

Segments

By segment

See full
Single Reportable$3.01M+221%

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$890.32M+67.5%
Enterprise value$642.72M+37.0%
P/E7.8×
P/S8.1×0.0×

Profitability

See full
Gross margin60.8%
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Theravance Biopharma's other income (expense)?
Theravance Biopharma (TBPH) reported other income (expense) of $3.01M in Q1 2026.
How has Theravance Biopharma's other income (expense) changed year-over-year?
Theravance Biopharma's other income (expense) increased by 220.9% year-over-year, from $939K to $3.01M.
What is the long-term trend for Theravance Biopharma's other income (expense)?
Over 4 years (2021 to 2025), Theravance Biopharma's other income (expense) has grown at a 74.0% compound annual growth rate (CAGR), from $1.11M to $10.17M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.